EPA-MA-Leucine Composition With Ratio-Tuned Muscle Protein Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compositions fail to effectively prevent or treat muscle loss and improve muscle function, particularly in subjects at risk or suffering from impaired muscle function, as they do not utilize the optimal ratio of eicosapentaenoic acid (EPA) and myristic acid (MA) in conjunction with leucine for enhancing muscle protein synthesis.
Innovation Solution
A composition comprising EPA and MA in a weight ratio of 0.8-1.8, preferably 0.9-1.7, with leucine, promotes muscle protein synthesis and muscle mass gain or maintenance by optimizing the EPA:MA ratio within this range, which can be administered as a nutritional or dietary supplement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compositions with EPA and MA are used, then muscle protein synthesis is stimulated, but the effect is insufficient compared to the optimal ratio composition
Solution Approach 1:
The patent applies parameter changes by optimizing the EPA:MA weight ratio to a specific range (0.8-1.8) to enhance muscle protein synthesis effectiveness. This quantitative adjustment of the fatty acid ratio transforms the composition from suboptimal to highly effective, directly resolving the contradiction between sufficient stimulation and optimal effectiveness.
Solution Approach 2:
The patent creates a composite nutritional composition combining EPA, MA, and leucine in specific proportions. This composite approach integrates multiple active ingredients with complementary functions - EPA and MA providing fatty acid benefits while leucine contributes amino acid stimulation - achieving synergistic effects that surpass individual components or non-optimized ratios.
2Quantity of substance
If fish oil with high DHA content is used, then muscle protein mass increases, but the EPA:MA ratio is not optimized for maximum benefit
Solution Approach 1:
The patent applies local quality by specifying precise requirements for the EPA:MA ratio (0.8-1.8) while allowing flexibility in other composition aspects. This targeted optimization focuses quality control on the critical fatty acid ratio parameter, ensuring maximum muscle protein synthesis benefit without unnecessarily constraining other formulation variables.
Solution Approach 2:
The patent transforms the composition by adjusting the EPA:MA ratio parameter to the optimal range, converting standard fish oil formulations into enhanced muscle-building compositions. This parameter optimization directly addresses the insufficient effectiveness of conventional fish oil by precisely controlling the relative amounts of EPA and MA.
3Reliability
If compositions outside the optimal EPA:MA ratio range are used, then muscle loss prevention is attempted, but the effectiveness is reduced
Solution Approach 1:
The patent resolves the effectiveness issue by changing the EPA:MA ratio parameter to the optimal range (0.8-1.8). This single parameter adjustment transforms suboptimal compositions into highly effective muscle loss prevention formulations, achieving reliable results without increasing overall formulation complexity.
Data Source
AI summary
The invention relates to compositions comprising EPA, MA and leucine for prevention and/or treatment of a disease or condition involving muscle decline or for improving muscle function.